Definitive Healthcare Corp. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; comparisons are primarily with FY2021. This is an annual report, not a standalone fourth-quarter earnings report. Definitive Healthcare sells subscription-based healthcare commercial intelligence through a SaaS platform and reported more than 3,000 customers at year-end.
Financial highlights
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $222.7 million | $166.2 million |
| GAAP gross profit / margin | $180.0 million / 80.9% | $125.5 million / 75.5% |
| Operating loss | $(41.3) million | $(25.0) million |
| Consolidated net loss | $(22.3) million | $(61.3) million |
| Adjusted EBITDA / margin | $63.7 million / 29% | $56.0 million / 34% |
| Cash from operating activities | $35.6 million | $25.2 million |
| Cash used in investing activities | $(248.9) million | $(46.7) million |
| Cash and cash equivalents | $146.9 million | $387.5 million |
| Short-term investments | $184.9 million | — |
| Term-loan principal outstanding | $266.4 million | $273.3 million |
Revenue grew 34%, primarily from expansion among existing customers, new customer additions and the Analytical Wizards acquisition. Subscription services contributed $217.0 million, about 97% of revenue. GAAP gross margin improved, while operating loss widened as operating expenses increased 47%, particularly in sales and marketing, product development and general and administrative costs. Adjusted EBITDA increased, but its margin declined from 34% to 29%; this non-GAAP measure excludes, among other items, equity compensation and acquisition-related expenses.
Net loss attributable to Definitive Healthcare Corp. was $6.0 million in FY2022, versus $17.7 million in FY2021; consolidated net loss is higher because it includes noncontrolling interests. The 2022 tax benefit was $17.2 million, substantially affecting the year-over-year consolidated net loss comparison.
Liquidity, debt and cash flow
At year-end, cash and short-term investments totaled $331.9 million, with an additional $75 million available on the undrawn revolving facility. The company reported $266.4 million of term-loan principal outstanding, at a 6.17% effective interest rate, with maturity in September 2026 and an approximately $220 million balloon payment at maturity. The loan is variable-rate; interest-rate swaps hedge part of the exposure. The company was in compliance with its financial covenants at December 31, 2022.
Operating cash flow rose to $35.6 million. Investing cash outflow was driven mainly by purchases of short-term investments ($338.0 million), partly offset by maturities ($153.7 million), and $56.3 million paid for the AW acquisition, net of cash acquired. Financing cash outflow included $12.9 million in member tax distributions and $6.9 million in term-loan repayments. Management said existing cash, investments and expected operating cash flow should meet liquidity needs for at least the next 12 months, subject to future performance and economic conditions.
Material changes and operating indicators
- Enterprise customer net dollar retention fell to 110% in 2022 from 120% in 2021; retention for customers above $17,500 ARR declined to 103% from 111%.
- Current remaining performance obligations increased to $183.5 million from $155.1 million; total remaining performance obligations were $277.0 million, compared with $250.5 million.
- Adjusted gross margin was 88%, unchanged from 2021, while adjusted EBITDA margin decreased from 34% to 29%.
- Equity-based compensation increased to $36.4 million from $10.0 million. Cash and cash equivalents fell, in part as the company invested in short-term securities and acquired AW.
- The February 2022 AW acquisition had total consideration of approximately $99.4 million, including the initial investment made in December 2021. AW’s post-acquisition revenue and net loss were not material, according to the filing.
Outlook, risks and unusual items
The filing provides no specific numerical revenue or earnings guidance. Management expects 2023 revenue growth and net dollar retention growth to be lower if macroeconomic conditions remain difficult. It cited longer sales cycles, stricter customer approvals and deferred purchasing decisions, particularly among life sciences and provider customers. The company expects cost of revenue as a percentage of revenue to remain consistent or modestly increase and anticipates higher interest expense on unhedged variable-rate debt.
In January 2023, the company announced a restructuring expected to reduce global headcount by approximately 55 employees. It estimated first-quarter 2023 pre-tax cash charges of $2.0–$2.5 million, primarily severance and related costs, with actions expected to be substantially complete by quarter-end.
- Goodwill: Goodwill was $1.323 billion. No impairment was recorded, but the reporting unit’s fair value was less than 10% above carrying value at year-end, leaving it exposed to future impairment if market capitalization or forecasts weaken.
- Tax Receivable Agreement: The recorded liability was $156.3 million. The company generally owes pre-IPO holders 85% of realized or deemed tax benefits; management stated the liability could rise to $265.4 million if additional benefits are considered realizable. Certain events, including a change of control, may accelerate payments.
- Data and regulatory exposure: Business depends on obtaining accurate, comprehensive data from third parties and complying with evolving privacy, cybersecurity, healthcare and AI-related requirements. A breach, loss of data access or regulatory change could affect customer demand and operations.
- Other risks: Competition, customer retention and expansion, macroeconomic uncertainty, acquisition integration, rising labor costs and variable-rate debt could pressure growth, profitability or liquidity.
- Contingencies and controls: Management said ordinary-course legal matters were not expected to have a material adverse effect. Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective at year-end.
Important facts for investors to verify
- Whether the deterioration in customer retention metrics and elongated sales cycles continues, and how it affects 2023 revenue and ARR growth.
- Cash generation and investment balances after the large 2022 cash decline, alongside debt amortization, variable-rate interest costs and covenant headroom.
- Progress on the workforce restructuring, realized savings and any operational or customer-service effects.
- Goodwill valuation assumptions and impairment headroom, given the less-than-10% fair-value cushion.
- TRA payment estimates, tax-benefit realizability and potential acceleration obligations.
- AW integration and the contribution of acquisitions to growth, margins and cash returns; also monitor the rising stock-based compensation burden.